These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16106018)

  • 1. Efforts aimed at reducing noise, data overload in microarrays.
    Tuma RS
    J Natl Cancer Inst; 2005 Aug; 97(16):1173-5. PubMed ID: 16106018
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of molecular genetic analysis in selecting antitumor therapy].
    Imianitov EN; Moiseenko VM
    Vopr Onkol; 2008; 54(2):121-32. PubMed ID: 18522159
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer gene microarrays pass muster.
    Twombly R
    J Natl Cancer Inst; 2006 Oct; 98(20):1438-40. PubMed ID: 17047189
    [No Abstract]   [Full Text] [Related]  

  • 4. DNA microarrays and data analysis: an overview.
    Eschrich S; Yeatman TJ
    Surgery; 2004 Sep; 136(3):500-3. PubMed ID: 15349092
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene microarrays in tumor diagnosis: opportunities and challenges.
    Giri D
    Med Health R I; 2005 Jul; 88(7):212-5. PubMed ID: 16184824
    [No Abstract]   [Full Text] [Related]  

  • 6. Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling.
    Simon R
    J Natl Cancer Inst; 2006 Sep; 98(17):1169-71. PubMed ID: 16954463
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
    Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
    J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarrays--the 21st century divining rod?
    He YD; Friend SH
    Nat Med; 2001 Jun; 7(6):658-9. PubMed ID: 11385496
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and validation of gene expression profile signatures in early-stage breast cancer.
    Desmedt C; Sotiriou C; Piccart-Gebhart MJ
    Cancer Invest; 2009 Jan; 27(1):1-10. PubMed ID: 19191098
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.
    Kim B; Lee HJ; Choi HY; Shin Y; Nam S; Seo G; Son DS; Jo J; Kim J; Lee J; Kim J; Kim K; Lee S
    Cancer Res; 2007 Aug; 67(15):7431-8. PubMed ID: 17671213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of therapeutically relevant multi-gene biomarker classifiers.
    Simon R
    J Natl Cancer Inst; 2005 Jun; 97(12):866-7. PubMed ID: 15956642
    [No Abstract]   [Full Text] [Related]  

  • 14. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
    J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HER-2/neu story: from oncogene through prognostic marker to therapeutic strategy determinant and monoclonal therapy.
    Mehigan BJ; Kerin MJ
    Eur J Surg Oncol; 1999 Apr; 25(2):111-2. PubMed ID: 10218450
    [No Abstract]   [Full Text] [Related]  

  • 16. Functional profiling methods in cancer.
    Dopazo J
    Methods Mol Biol; 2010; 576():363-74. PubMed ID: 19882272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DualChip microarray as a new tool in cancer research.
    Gillet JP; de Longueville F; Remacle J
    Expert Rev Mol Diagn; 2006 May; 6(3):295-306. PubMed ID: 16706734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile analysis in laryngeal cancer by high-density oligonucleotide microarrays.
    Markowski J; Oczko-Wojciechowska M; Gierek T; Jarzab M; Paluch J; Kowalska M; Wygoda Z; Pfeifer A; Tyszkiewicz T; Jarzab B; Niedzielska I; Borgiel-Marek H
    J Physiol Pharmacol; 2009 May; 60 Suppl 1():57-63. PubMed ID: 19609014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.
    Winnepenninckx V; van den Oord JJ
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1611-31. PubMed ID: 18020928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.